Dr. Mohamad Haydar

M.D in Hematology since 1998 from JOSEPH FOURRIER University in Grenoble, France.
Head of Hemato-Oncology at Bahman Hospital.
Head of Oncology Unit in Nabatieh Governmental University Hospital.
Member in several Local, regional and international Hemato-Oncology Societies.
Member of Lebanese society of medical Oncology (LSMO)
Main clinical and research interest are mainly in Lymphoma and CML.
Co-author in several publications and research.

 

Prof. Salam Al Kindi

Professor and consultant hematologist at Sultan Qaboos University Hospital in Oman, graduated from Trinity college University of Dublin Ireland, he received general medicine as well as  hematology/ oncology training in Dublin Ireland as well as the Fred Hutch cancer center in Seattle USA  where he received training in bone marrow transplant. He was appointed as head of department of  Sultan Qaboos University for 10 years and previously he held the position of deputy director of Sultan Qaboos university for clinical affairs for 5 years His research interests include sickle cell disease , chronic leukemia and autoimmune disorders with about 100 articles published in international peer reviewed journals.

 

Prof. Mohamad Bradai

Hematology department head in CAC Blida Medicine department in Algeria. Head Medicine at Medicine Faculty of Blida International publications in Blood, transfusion practice Books on hereditary pathology of red blood cell. He is the coordinator of the autoimmune cytopenia’s working group, Director of the research group on hemoglobinopathies French network member on red blood cell pathology.

 

Dr. Pierre Laneuville

Associate Professor (GFT-U) in the Department of Medicine and Oncology at McGill University, the former Head of Hematology for the McGill University Health Center (MUHC).

Dr. Laneuville obtained an Honours B.Sc. in Biochemistry at McMaster University, his medical degree at the University of Ottawa, trained in internal Medicine at McGill University, and completed his hematology sub-specialty and research training with Dr. B.A. Cooper at the Royal Victoria Hospital and McGill University from 1985 to 1989. He then joined the staff and faculty at the Royal Victoria Hospital and McGill University and has focused his clinical and laboratory research activities on hematological malignancies.  Dr. Laneuville is best known for his research on the molecular mechanisms underlying the genesis and transformation of chronic myelogenous leukemia.  

He is a past President of the Canadian Hematological Society and Chairman of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia (CCGM-CML).  He has served on numerous basic and clinical research panels including the Medical Research Council of Canada, the Leukemia Research Fund of Canada, and the National Cancer Institute of Canada Clinical Trials Hematology Executive.  

He has held a number of research grants supported by the MRC, LRFC, CRSI, MSSC, and is actively engaged in clinical trials for hematological malignancies and stem cell transplantation. He is currently the Medical Director of the McGill University Health Centre Research Institute Cellular Therapy Laboratory.